SLC25A10

Across TCGA pan-cancer cohorts, SLC25A10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC25A10 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher SLC25A10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC25A10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA, LIHC, and SKCM are the cancer types where SLC25A10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.038	0.841	<.001	18	view →
LIHC	DFS	Median	All	0.046	0.553	<.001	15	view →
SKCM	DFS	Median	All	0.198	0.728	.015	12	view →
GBM	OS	Median	All	0.089	0.413	.023	6	view →
UCEC	DFS	Median	All	1.000	0.831	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC25A10–THCA (DFS)

Open the THCA breakdown →